Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49
Trial details
- Registry ID
- NCT07284654
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as Capvaxive
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49NCT07284654 | PCVX | Phase 3 | Completed | 2026-09-17Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |